WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS

Antiseptic and antiinfective preparations for systemic use specifically used in urinary tract infections, see J01.
Antiinfectives for systemic use, see group J.
Gynecological antiinfectives and antiseptics, see G01.


G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY

G04CA Alpha-adrenoreceptor antagonists

Alfuzosin and terazosin used in the management of urinary obstruction caused by benign prostatic hypertrophy, are classified here, while other alpha-adrenoreceptor blocking agents used both in the management of urinary obstruction and hypertension (e.g. doxazosin) are classified in C02CA.

G04CB Testosterone-5-alpha reductase inhibitors

Combinations/combination packages with alpha-adrenoreceptor antagonists are classified in G04CA.

G04CX Other drugs used in benign prostatic hypertrophy

Last updated: 2024-01-26